Search Result

Results for "

ABHD6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Carboxylesterase (CES) (1) DAGL (3) Drug Derivative (1) Drug Metabolite (1) Endogenous Metabolite (1) FAAH (3) Histamine Receptor (1) MAGL (23) Phospholipase (1) Reference Standards (3) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (2) Inflammation/Immunology (4) Metabolic Disease (9) Neurological Disease (10)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136924

FP-Biotin	FAAH	Others
FP-biotin is a potent organophosphorus toxicant, well-suited for searching for new biomarkers of organophosphorus toxicants exposure. FP-Biotin quantifies FAAH, ABHD6, and MAG-lipase activity. FP-biotin is used for studies with plasma because biotinylated peptides are readily purified by binding to immobilized avidin beads .

HY-100337

WWL70 2 Publications Verification	MAGL	Neurological Disease
WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC₅₀ of 70 nM.

HY-152148

JZP-MA-11	MAGL	Neurological Disease
JZP-MA-11 is a brain-penetrant positron emission tomography (PET) ligand targeting the brain endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC₅₀ value of 126 nM. [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .

HY-124314

LEI-106	MAGL DAGL	Metabolic Disease
LEI-106 is a dual *ABHD6* and DAGL-α inhibitor, with a K_i of 0.8 μM for ABHD6, and an IC₅₀ of 18 nM and a K_i of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome .

HY-120215

KT203	MAGL	Metabolic Disease
KT203 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC₅₀ of 0.31 nM in Neuro2A cells .

HY-101457

JZP-430	MAGL	Metabolic Disease
JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC₅₀ of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .

HY-120177

KT182	MAGL	Others
KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC₅₀ of 0.24 nM in Neuro2A cells .

HY-120171

DH-376	DAGL MAGL	Metabolic Disease
DH-376 is a potent diacylglycerol lipase inhibitor with pIC₅₀ values of 8.6 and 8.9 for ABHD6 and DAGLα, respectively. DH-376 prevents fasting-induced refeeding of mice . DH-376 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-110148

WWL113	Carboxylesterase (CES)	Metabolic Disease
WWL113 is a selective and orally active Ces3 and Ces1f inhibitor, with IC₅₀ values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases) .

HY-18544

AA38-3	MAGL FAAH	Metabolic Disease
AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH .

HY-126031

(R)-KT109	DAGL	Inflammation/Immunology
(R)-KT109 is a peripherally restricted serine hydrolase inhibitor that cannot cross the blood-brain barrier. (R)-KT109 irreversibly inhibits ABHD6, DAGLα and DAGLβ via carbamoylation of the active-site serine. (R)-KT109 exerts selective inhibitory effects on serine hydrolases in mouse brains, with pIC₅₀ values of 8.6, 9.1 and 8.2 against human ABHD6, DAGLα and DAGLβ, respectively. (R)-KT109 effectively reduces the levels of 2-arachidonoylglycerol, arachidonic acid, eicosanoids and TNF-α. (R)-KT109 is widely used in studies of metabolic syndrome-related diseases and neuroinflammation .

HY-132310

MAGL-IN-4	MAGL	Neurological Disease
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .

HY-RS00097

ABHD6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABHD6 Human Pre-designed siRNA Set A contains three designed siRNAs for ABHD6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABHD6 Human Pre-designed siRNA Set A ABHD6 Human Pre-designed siRNA Set A

HY-RS16727

Abhd6 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abhd6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abhd6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abhd6 Mouse Pre-designed siRNA Set A Abhd6 Mouse Pre-designed siRNA Set A

HY-126031A

(S)-KT109	Endogenous Metabolite	Others
(S)-KT109 is an inhibitor of diacylglycerol lipase β (DAGLβ) with low inhibitory activity (IC50 = 39.81 nM). (S)-KT109 has relatively low inhibitory activity against DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol (IC50 = 794.3 nM). (S)-KT109 also has relatively low inhibitory activity against α/β-amidase domain-containing 6 (ABHD6) (IC50 = 630.9 nM) .

HY-121422

JZP-361	MAGL Histamine Receptor	Inflammation/Immunology
JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC₅₀ of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .

HY-125143

ABC34	MAGL	Metabolic Disease
ABC34 is an inactive control compound of JJH260. ABC34 does not inhibit the fluorophosphonate reactivity or fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1. ABC34 can inhibit both *ABHD6* and PPT122 .

HY-RS23163

Abhd6 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abhd6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Abhd6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abhd6 Rat Pre-designed siRNA Set A Abhd6 Rat Pre-designed siRNA Set A

HY-158339

ABHD antagonist 2	MAGL	Neurological Disease
ABHD antagonist 2 (Compound 9) is an antagonist for alpha/beta-Hydrolase domain containing 6 (ABHD6), with IC₅₀ <0.001 μM. ABHD antagonist 2 exhibits good binding ability with *ABHD6, with IC₅₀* of 0.002 μM .

HY-114926

KT185	MAGL	Neurological Disease
KT185 is an orally-bioavailable, brain-penetrant and selective *ABHD6* inhibitor, with an IC₅₀ 0.21 nM in Neuro2A cells .

HY-117722

JW 618	MAGL	Others
JW 618 is a selective *ABHD6* inhibitor, with IC₅₀s of 38 and 13 nM for mouse and rat ABHD6 .

HY-120126

ML378 CID71710938; JJH-254	Phospholipase	Metabolic Disease
ML378 (CID71710938) is a dual LYPLA1 and LYPLA2 inhibitor, with IC₅₀s of 122 nM and 245 nM respectively. ML378 also shows potent inhibition of *ABHD6* (IC₅₀ = 3.15 nM). ML378 can be used for elucidating the patho/physiological roles of the LYPLA1 and LYPLA2 .

HY-132246

WWL123 analogue-1	MAGL	Neurological Disease
WWL123 analogue-1 is an analogue of WWL123. WWL123 is a potent and selective *ABHD6* inhibitor with an IC₅₀ of 430 nM . WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylenetetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice .

HY-152152

JZP-MA-13	MAGL	Neurological Disease
JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC₅₀ of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 .

HY-116793

Dimepiperate MY 93; Yukamate	MAGL	Others
Dimepiperate (MY 93) is a thiocarbamate (TC) pesticide. Dimepiperate has potential off-targets effect for the inhibition of ABHD6 .

HY-116793R

Dimepiperate (Standard) MY 93 (Standard); Yukamate (Standard)	Reference Standards MAGL	Others
Dimepiperate (Standard) is the analytical standard of Dimepiperate. This product is intended for research and analytical applications. Dimepiperate (MY 93) is a thiocarbamate (TC) pesticide. Dimepiperate has potential off-targets effect for the inhibition of ABHD6 .

HY-116212

JCP-170	MAGL	Cancer
JCP-170, a substituted chloroisocoumarin, is an *ABHD6* inhibitor. JCP-170 robustly and reproducibly inhibits metastatic seeding of the murine cell line 0688M and both human pancreatic ductal adenocarcinoma (PDAC) cell lines .

HY-158338

ABHD antagonist 1	MAGL	Others Neurological Disease Inflammation/Immunology Cancer
ABHD antagonist 1 possesses *ABHD6* (α/β-Hydrolase domain containing 6) inhibitory activity, involving the regulation of biochemical pathways involved in *ABHD6, thereby affecting cell function and inflammatory response. ABHD* antagonist 1 can be used in pain, neuropathic diseases, inflammatory diseases. Autoimmune diseases, metabolic diseases, and cancer research .

HY-110178

WWL123	MAGL	Inflammation/Immunology
WWL123, a carbamate-based compound, is a potent and selective *ABHD6* inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .

HY-13056R

SMND-309 (Standard)	Drug Metabolite Reference Standards	Neurological Disease
Dimepiperate (Standard) is the analytical standard of Dimepiperate. This product is intended for research and analytical applications. Dimepiperate (MY 93) is a thiocarbamate (TC) pesticide. Dimepiperate has potential off-targets effect for the inhibition of ABHD6 .

HY-103463

SA57	FAAH MAGL	Neurological Disease
SA57 is a potent, selective FAAH inhibitor with IC₅₀s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC₅₀s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC₅₀ of 850 nM), but not other brain serine hydrolases .

HY-101457R

JZP-430 (Standard)	MAGL Reference Standards	Metabolic Disease
JZP-430 (Standard) is the analytical standard of JZP-430 (HY-101457). This product is intended for research and analytical applications. JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .

HY-184029

PF-7845yne	Biochemical Assay Reagents Drug Derivative	Others
PF-7845yne is a clickable analogue of PF-7845. PF-7845yne serves as a pharmacological probe to investigate effects of targeting the FAAH-anandamide pathway .

Cat. No.	Product Name		Classification

HY-120171

DH-376		Alkynes
DH-376 is a potent diacylglycerol lipase inhibitor with pIC₅₀ values of 8.6 and 8.9 for ABHD6 and DAGLα, respectively. DH-376 prevents fasting-induced refeeding of mice . DH-376 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-184029

PF-7845yne		Alkynes
PF-7845yne is a clickable analogue of PF-7845. PF-7845yne serves as a pharmacological probe to investigate effects of targeting the FAAH-anandamide pathway .

ABHD6 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
ABHD6 Human Pre-designed siRNA Set A contains three designed siRNAs for ABHD6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abhd6 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Abhd6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abhd6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abhd6 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Abhd6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Abhd6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: